Gilead Sciences (GILD) granted FDA approval for Quad pill, Stribild
Tweet Send to a FriendGet Alerts GILD Hot Sheet
Down)
Trade GILD Now!
Gilead Sciences Inc. (Nasdaq: GILD) granted FDA approval for Quad pill, Stribild, for HIV.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- Hologic (HOLX) Announces FDA Approval of C-View 2D Imaging for or Breast Cancer Screening
- AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
Create E-mail Alert Related Categories
FDA, Hot FDA News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
